# Pharmacokinetic and Pharmacodynamic Effects of Escitalopram Depending on Genetic Polymorphisms of the ABCB1-gene

> **NCT00550485** · NA · COMPLETED · sponsor: **Max-Planck-Institute of Psychiatry** · enrollment: 79 (actual)

## Conditions studied

- Pharmacokinetics

## Interventions

- **DRUG:** escitalopram

## Key facts

- **NCT ID:** NCT00550485
- **Lead sponsor:** Max-Planck-Institute of Psychiatry
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2018-07-06
- **Final completion:** 2018-07-06
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2019-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00550485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00550485, "Pharmacokinetic and Pharmacodynamic Effects of Escitalopram Depending on Genetic Polymorphisms of the ABCB1-gene". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00550485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*